← Eichor
Study identifier: NCT07652879 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome

Condition: POEMS Syndrome  ·  Sponsor: Shanghai Changzheng Hospital

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study is a single-center, prospective, open-label clinical study to evaluate the efficacy and safety of KCD(Carfilzomib/Cyclophosphamide/Dexamethasone) regimen in subjects with newly diagnosed POEMS Syndrome.

This description comes directly from the study's public registry record.

Talk to the study team

Haiyan He, Dr.  ·  +86 13661513012  ·  doctorhehaiyan@126.com

Xuerou Yu

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Changzheng HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07652879